ECLOBIOSENS

Electrochemiluminescent biosensor for screening of coeliac disease

Coordinatore	UNIVERSITAT ROVIRA I VIRGILI    more  Organization address address: CARRER DE ESCORXADOR city: TARRAGONA postcode: 43003 contact info Titolo: Dr. Nome: Ciara Kathleen Cognome: O'sullivan Email: send email Telefono: 34977558740 Fax: 34977559667
Nazionalità Coordinatore	Spain [ES]
Totale costo	0 €
EC contributo	161˙899 €
Programma	FP7-PEOPLE Specific programme "People" implementing the Seventh Framework Programme of the European Community for research, technological development and demonstration activities (2007 to 2013)
Code Call	FP7-PEOPLE-IIF-2008
Funding Scheme	MC-IIF
Anno di inizio	2010
Periodo (anno-mese-giorno)	2010-06-01   -   2012-05-31

 Partecipanti

#	participant	country	role	EC contrib. [€]
1	UNIVERSITAT ROVIRA I VIRGILI  Organization address address: CARRER DE ESCORXADOR city: TARRAGONA postcode: 43003 contact info Titolo: Dr. Nome: Ciara Kathleen Cognome: O'sullivan Email: send email Telefono: 34977558740 Fax: 34977559667	ES (TARRAGONA)	coordinator	161˙899.60

Mappa

 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

 Obiettivo del progetto (Objective)

'The overall objective of ECLOBIOSENS is to develop a generic technological platform for point-of-care diagnostics capable of simultaneous genomic and proteomic electrochemiluminescent detection. As a model system biosensor arrays for the screening of coeliac disease will be developed based on the simultaneous detection of nucleic acids (HLA typing) and protein molecular markers (auto-antibodies) associated with genetic predisposition and early diagnosis of coeliac disease. The combined detection strategy could be used for general population screening, or just the HLA typing could be used for neonatal screening; or alternatively just the auto-antibody detection could be used for monitoring compliance with the identified diet, or recurrence of the disease due to non-compliance. Additionally false negatives due to coeliacs with IgA deficiency will be avoided by screening for both IgA and IgG auto-antibodies. Together with classical assay formats, novel biomolecule detection schemes based on supramolecular associations will be developed with the aim to fine tune the specificity and sensitivity of the assays. The advantages of the proposed biosensor system include their ease of use, their sensitivity, their inherent selectivity (preventing problems due to interfering substances), their versatility (allowing ‘in-field’ use) and their cost effectiveness.'